A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
A long-awaited update from Amgen’s Kras inhibitor shows waning single-agent efficacy – a situation apparently pre-empted by Mirati.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Pivotal data are expected soon on tezepelumab, Amgen and Astrazeneca's shot at non-eosinophilic asthma.
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.